← Back to Search

CAR T-cell Therapy

BAFF CAR-T for Non-Hodgkin Lymphoma

Phase 1
Recruiting
Led By Paolo F. Caimi, MD
Research Sponsored by Luminary Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air
Cardiac ejection fraction of >50%, and no evidence of pericardial effusion, as determined by an echocardiogram
Must not have
History of allogeneic hematopoietic stem cell transplantation
Active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new immune cell therapy for patients with non-Hodgkin lymphoma who haven't responded to other treatments. The therapy involves modifying the patient's own immune cells to better recognize and attack their cancer.

Who is the study for?
Adults over 18 with non-Hodgkin lymphoma that's come back after at least two treatments or hasn't responded to chemo can join. They need good liver, kidney, heart, and lung function, no brain lymphoma, and must use effective birth control. Those who've had recent other cancer treatments or have certain health issues like severe heart problems or active infections can't participate.
What is being tested?
The trial is testing a new therapy called BAFF CAR-T cells for people whose non-Hodgkin lymphoma didn't respond to previous treatments including CD19 targeted CAR-T cells. It aims to find the safest dose of BAFF CAR-T and see how well it works against the disease.
What are the potential side effects?
Potential side effects may include immune system reactions affecting different parts of the body, symptoms related to infusion such as fever or chills, tiredness, changes in blood counts leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My oxygen level is 92% or higher without extra oxygen.
Select...
My heart pumps well and I don't have fluid around it.
Select...
My non-Hodgkin lymphoma has returned after 2+ treatments or is resistant to chemotherapy.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I do not have lymphoma in my brain or spinal cord.
Select...
I agree to either not have sex or use birth control, and not donate sperm.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a stem cell transplant from a donor.
Select...
I have an active cancer other than non-dangerous skin cancer or early-stage cancers.
Select...
I have the most severe form of heart failure.
Select...
I have had a stem cell transplant within the last 6 weeks.
Select...
I am experiencing symptoms of graft-versus-host disease.
Select...
My lymphoma or leukemia has spread to my brain or spinal cord.
Select...
I am HIV positive.
Select...
I am currently receiving IV treatment for an infection.
Select...
I do not have a history of significant brain-related health issues like epilepsy or severe brain injuries.
Select...
I have another cancer that needs treatment through the bloodstream.
Select...
My tests show early signs of a bone marrow disorder before starting treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To determine recommended phase II dose of human LMY-920.
Secondary study objectives
To determine incidence of adverse events.
To determine incidence of anti- LMY-920 antibodies.
To determine the complete response rate.
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: LMY-920 dose escalationExperimental Treatment1 Intervention
Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Non-Hodgkin's Lymphoma (NHL) include CAR-T cell therapy, monoclonal antibodies, and small molecule inhibitors. CAR-T cell therapy involves modifying a patient's T cells to express chimeric antigen receptors (CARs) that specifically target and kill lymphoma cells. Monoclonal antibodies, such as rituximab, target specific proteins on the surface of lymphoma cells, leading to their destruction. Small molecule inhibitors, like ibrutinib, block signaling pathways essential for lymphoma cell survival and proliferation. The BAFF CAR-T cells being studied aim to target the BAFF receptor on lymphoma cells, offering a novel approach to treatment. These targeted therapies are crucial for NHL patients as they provide more precise and effective treatment options, potentially leading to better outcomes and fewer side effects compared to traditional chemotherapy.

Find a Location

Who is running the clinical trial?

Luminary TherapeuticsLead Sponsor
2 Previous Clinical Trials
48 Total Patients Enrolled
Case Comprehensive Cancer CenterOTHER
469 Previous Clinical Trials
33,450 Total Patients Enrolled
Paolo F. Caimi, MDPrincipal InvestigatorCleveland Clinic Taussig Cancer Institute

Media Library

BAFF CAR-T (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05312801 — Phase 1
Non-Hodgkin's Lymphoma Research Study Groups: LMY-920 dose escalation
Non-Hodgkin's Lymphoma Clinical Trial 2023: BAFF CAR-T Highlights & Side Effects. Trial Name: NCT05312801 — Phase 1
BAFF CAR-T (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05312801 — Phase 1
~5 spots leftby May 2025